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In Reply This systematic review and meta-analysis1 addressed
1 of 6 research questions that comprised a larger project funded
by the Agency for Healthcare Research and Quality in partner-
ship with the National Heart, Lung, and Blood Institute. The
protocol was registered with PROSPERO (CRD42016047985)
and the final report is publicly available.2
Prior to publication, the draft report was posted for pub-
lic comment and underwent peer review. This project was de-
signed and conducted by a team without related conflicts of
interest and no biases toward a particular result. As such, to
our knowledge, no unpublished data were intentionally re-
moved from any of the analyses.
Regarding the analysis comparing SMART with a higher
dose of inhaled corticosteroids and LABA controller therapy
with an end point of exacerbation risk, the 2 studies in ques-
tion were excluded from the pooled estimate for valid rea-
sons. First, the study by Ställberg et al3 included patients with
both the same and higher inhaled corticosteroid doses in the
comparator group; therefore, it was not pooled with studies
that examined solely higher dosing.
Second, the study by Pavord et al4 did not specifically pro-
vide the number of study participants in each group who ex-
perienced a severe exacerbation; rather, they reported the time
to first exacerbation or mean rate of severe exacerbations per
patient-year. Therefore, the results shown in Figure 3 repre-
sented the best available evidence at the time for the out-
come of exacerbation risk.
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Lowering the P Value Threshold
To the Editor Dr Ioannidis1 proposed lowering the P value thresh-
old to .005 for medical studies. This proposal builds on the sug-
gestion by Benjamin et al,2 who were concerned that a P value
threshold of .05 contributed to the nonreproducibility of stud-
ies through a high false-positive rate. However, the proposal
for a lower P value threshold may provoke misunderstanding
of the use of P values and thereby hinder innovation.
Several risk factors influence the gap between actual
and expected false-positive rates.2 However, biased esti-
mates can also result from selection bias, information bias,
or confounding bias, with false-positive findings more likely
to be published.
In addition, failed replication occurs in cases of unknown
heterogeneity among study populations. Yet simply reduc-
ing the P value threshold does not attenuate these problems.
Instead, it may increase the possibility of false-negative re-
sults, impede the development of potential therapeutic agents
at an early phase, increase needed sample sizes, lessen study
feasibility, and aggravate P value hacking and data manipula-
tion. Thus, the proposal to reduce the P value threshold ad-
dresses only superficial problems rather than the essential con-
tributing factors.
We believe that resolving this issue begins with study
design and supervision. First, potential bias should be con-
sidered during study design. Random sampling ensures the
representativeness of research samples. Random allocation
avoids potential confounding bias. Repeating experiments
exposes coincidental results and ensures the reproducibility
of findings.
Second, we prefer study replication over a low-
ered significance threshold for reducing the risk of false-
positive results. Although this would require a larger
number of participants, the combined false-positive rate
of the original and replication studies would not exceed
.05 × .05 = .0025, and replication would yield lower risk
and improved reproducibility.
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Third, study protocol repository and registration sys-
tems should be promoted widely for accessibility to the sci-
entific community. Modifications to the study protocol should
be submitted to and approved by the system. Public accessi-
bility to original experimental records also would improve re-
producibility.
Fourth, the definition of the P value and its threshold
should be treated objectively.3,4 Effect size should be consid-
ered ahead of statistical significance, and both should be used
for better decision making. Different P value thresholds may
be appropriate for different research fields (eg, .05 for tradi-
tional analysis, 5 × 10−8 for genome-wide research) and study
objectives (.10 or .05 for screening phase, .05 or .01 for con-
firmation phase). New approaches, such as the Bayes and causal
inference methods, also should be considered.
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To the Editor The Viewpoint by Dr Ioannidis discussed the re-
cent proposal by a coalition of 72 methodologists to lower the
statistical significance threshold to .005.1,2 Ioannidis acknowl-
edged limitations of this proposal; however, his Viewpoint did
not discuss any financial implications of this change.1 Power-
ing randomized clinical trials (RCTs) and prospective obser-
vational studies at an α level of .005 would translate into con-
siderably higher costs associated with larger sample sizes.
The increased costs associated with powering prospec-
tive studies at the .005 level could have serious repercus-
sions, especially for publicly funded trials. First, in the cur-
rent hypercompetitive environment in which many deserving
studies do not get funded, these cost increases would result
in an even higher number of clinically relevant studies that re-
main unfunded. In the absence of unlimited resources to sup-
port research, this proposal inevitably raises the question of
whether limited funds should be spent on a few highly pow-
ered studies vs supporting a greater number of studies pow-
ered at the .05 level.
Second, this change would affect RCTs supporting new
drug approvals. In addition to incentivizing the selection of sur-
rogate outcomes as end points, as acknowledged by Ioannidis,1
the increased financial risk would motivate manufacturers to
adopt more conservative approaches when making decisions
regarding whether to support new molecules through the clini-
cal phase. This would ultimately lead to delays in innovation
and access to new therapies.
Third, lower P value thresholds would be particularly prob-
lematic in the design of studies for rare diseases, given the
added difficulty in recruitment.
Although we commend efforts to mitigate the misuse of
P values, we believe that lowering the statistical significance
threshold would first require a broader debate that accounts
for its consequences on access to research findings and avail-
ability of new therapies.
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To the Editor Changing the P value threshold to .005 does not
solve the issue of how to interpret P values.1 It simply shifts
the burden of proof to require a more extreme difference.
Uncertainty regarding the potential benefit of a therapy that
demonstrated a clinically meaningful but now statistically non-
significant result would increase.2 The demonstration of the
reproducibility of experiments, a cornerstone of the scien-
tific method, would be diminished and restricted to those
therapies showing large differences (together with large sample
sizes). Clinicians may feel abandoned.
To illustrate, a study of long-term survival of patients re-
ceiving intraperitoneal chemotherapy showed a clinical ben-
efit with a median survival of 5.2 years vs 4.3 years in the con-
trol group, yet the P value was only .04.3 Under the proposed
threshold, the result would not be statistically significant, yet
clinicians would consider the difference clinically important.
The real problem is with the scientific interpretation of the
statistical results and not the choice of significance level.4 It
makes sense to place more effort on explaining the clinical rel-
evance of a result rather than simply the statistical meaning.
The consequences of lowering the threshold include how to
interpret harm in the safety and subgroup analyses with non-
significant interaction tests.
For example, the change in the standard treatment for pa-
tients with K-ras wild-type metastatic colorectal cancer might
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have been missed because the P value for interaction for a dif-
ferential treatment effect on survival between the K-ras mu-
tation and wild type was only .01.5
Lowering the P value threshold would be detrimental to
interpreting signal-finding associations in multivariable analy-
ses and systematic reviews and yield little scientific gain and
potentially major scientific loss.
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To the Editor P values are a common measure in most observa-
tional studies and RCTs. Researchers have long attached un-
due importance to significant P values despite the fact that
P values by themselves have no clinical interpretation. The rec-
ommendation by Dr Ioannidis1 to replace the arbitrary α level
of .05 as the threshold of statistical significance with a lower
value is laudable but begs for elaboration.
Statistical methods that assess sampling uncertainty, such
as P values, have been the foundation for quantitative medi-
cal research since World War II.2 However, P values are not of-
ten replicated in similar studies, and their definition is not di-
rectly associated with reproducibility.3
Scientific findings are not valid if they cannot be repro-
duced and are highly variable. Although other methodologi-
cal issues relate to reproducibility, the P value is arguably at
the root of the problem, given its wide variability and irrepro-
ducibility from study to study.4 The irreproducibility of P val-
ues was demonstrated using a simulation with data from a pub-
lished RCT.5 The probability of attaining another statistically
significant P value varied widely on replication.
Statistical power alone determined the distribution of P val-
ues and varied with sample size and effect size. Given the vari-
ability in replicated P values, lowering the α level to .005 or
even .001 would make little difference in interpreting and ap-
plying the results clinically.
Categorizing findings as either statistically significant or
not is a false dichotomy. Confidence intervals (CIs) share some
of the weaknesses of P values. Of the means replicated in the
simulation, 85.4% fell within the original 95% CI. However, the
advantage of CIs is that they are more easily understood. Val-
ues outside the CI are not likely to exist in the population. When
interpreted out of context, using P values without CIs can be
misleading and potentially lead to biased inferences from clini-
cal studies.
Medicine needs a more critical understanding of statisti-
cal power and inferences. Optimal statistical reasoning should
consider P values in conjunction with CIs while contextualiz-
ing the findings in the clinical context.
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To the Editor Dr Ioannidis argued that the proposal to lower the
P value threshold for claiming statistical significance from .05
to .005 is a temporary solution to improve statistical infer-
ence and suggests additional training in methods and statis-
tics for the scientific workforce.1,2
To people who do not understand complex statistics, the
P value threshold of .05 is a rule of thumb for claiming statis-
tical significance. The rule can be safely applied because the
threshold is .05 regardless of the underlying statistics, with a
few exceptions. We agree with Ioannidis that improving sta-
tistical literacy may be unachievable2 but believe that replac-
ing 1 rule of thumb with 2 others can aid researchers in assess-
ing scientific claims.
First, results vary with the methods. Statistical estimates
may vary with differences in the selection of the study popu-
lation, length of follow-up, and the measurement of the
variables.3 The likelihood of such differences is relevant when
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studies are performed using data that are not specifically col-
lected for the research question at hand such as from elec-
tronic health records or biobanks. The variables in these data
collections may not be measured ideally, and relevant con-
founders may be missing. If the results may be different with
optimal study design and data collection, the P values will vary.
Knowing that methodology affects the estimates and the P val-
ues prevents taking them too literally.
Second, each study is only 1 piece of the puzzle. Scientific
claims and knowledge in the health sciences primarily follow
from inductive reasoning that allows scientists to infer future
instances from observed instances, across studies, through
generalizations.4 The results of a single study represent only
1 piece of evidence, and the results of other studies may
make a claim more or less likely. These other studies can be
similar, aiming at replication, or different, contributing
experimental evidence from, for example, animals or cells.5
Only the combined evidence determines the likelihood of the
claim being true.
Science thrives on high-quality data, statistics, and rea-
soning. Ioannidis’ aim to improve statistical literacy is a long-
term project worthy of support. Strengthening scientific rea-
soning through 2 simple rules that discourage overreliance on
the P value might be an immediate and effective substitute.
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In Reply Drs Wei and Chen list several approaches that can be
used to minimize bias and increase the reproducibility and util-
ity of future studies. There is no reason why all these efforts
cannot be pursued. Currently there is a rich discussion about
ways to improve research.1,2 Changing the P value threshold
will not hinder such improvements. Moreover, these pro-
posed improvements cannot salvage studies already per-
formed, whereas changing the P value threshold may better
calibrate the interpretation of past literature.
Dr Hernandez and colleagues are concerned about higher
costs associated with larger required sample sizes, a higher
number of unfunded trials given limited public funds, and a
delay in access to new therapies. Their reasoning assumes that
the clinical trials agenda is optimized and rationally driven with
careful, clinically relevant, and statistically solid power cal-
culations. This is far from the reality; most trials are notori-
ously underpowered, spuriously powered for irrelevant out-
comes, heavily biased, or a combination of these. Instead of
having 1 million mostly useless trials, a focus on fewer, bet-
ter, more conclusive ones should help.
Regardless, sometimes clinical and implementation deci-
sions may need to be adopted with only “suggestive” rather
than “statistically significant” evidence. For rare diseases, this
situation may be more common, but the terminology (“sug-
gestive”) is then appropriate: it conveys that less is known than
would be desired. In extremely rare conditions with minimal
evidence, decisions may be made even with a P value greater
than .05, trying to optimally balance the consequences and cost
of false-positive and false-negative results.3
I do not share the concerns of Wei and Chen and Hernan-
dez and colleagues about slowed innovation. Better decision
rules lead to more efficient innovation, with better discrimi-
nation of what matters and what does not, and with fewer pur-
suits of false leads.
Mr Gebski and Dr Byth suggest that many clinically mean-
ingful differences would be dismissed. Of course, interpret-
ing the results of clinical studies should focus primarily on their
clinical rather than their statistical significance. However, most
of the effects in the range of P values between .005 and .05 in
the past literature are not clinically significant. I acknowl-
edged in the Viewpoint that exceptions do exist.4
For “suggestive” statistical significance with clear clinical
significance, the latter should have priority. The 2 examples
that Gebski and Byth provide as major failures of the P value
threshold less than .005 demonstrate, in fact, that the rule
works. The study of long-term survival of patients receiving
intraperitoneal chemotherapy in ovarian cancer shows a
P value of .002 for the survival benefit,5 not .04 as they
claim. For K-ras and colorectal cancer, the P value of .01
is for survival (“suggestive”) but the P value is less than .001
(“statistically significant”) for progression-free survival.6
I agree with Dr Barach and colleagues regarding CIs and
I favor contextualizing the findings in the clinical context. The
simulation study adds to the literature about how P values are
misinterpreted. However, their claim that “values outside the
[95%] CI are not likely to exist in the population” is optimis-
tic. It holds true only if multiple assumptions are met such as
lack of any biases. Use of 95% CIs suffers from some, but not
all, of the problems of P value thresholds less than .05.
I am sympathetic with the 2 additional rules of thumb
that Drs Janssens and Penders propose to sensitize more
clinical researchers, clinicians, and users of the scientific lit-
erature. However, having to resort to oversimplified rules of
thumb perpetuates the current concept that widespread sta-
tistical illiteracy and innumeracy should be taken for
granted. Scientific reasoning needs solid methodological
training. Rules of thumb (including P < .005) are mostly tem-
porizing measures.
John P. A. Ioannidis, MD, DSc
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CORRECTION
Incorrect Medication Reported: In the News From the Food and Drug Adminis-
tration item entitled “Generic for Opioid Use Disorder,”1 published in the July 17,
2018, issue of JAMA, an incorrect medication was reported. In the second para-
graph, the second sentence should have read as follows: “Buprenorphine, naltrex-
one, and methadone are FDA-approved to help patients who misuse opioids.” This
article was corrected online.
1. Voelker R. Generic for opioid use disorder. JAMA. 2018;320(3):228.
Error in Figure: In the Original Investigation entitled “Effect of Loading Dose
of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on
Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-
PCI Randomized Clinical Trial”1 published in the April 3, 2018, issue of JAMA,
an error occurred in a figure. In Figure 3, the last 2 row labels were switched.
The second-to-last row should have been labeled “Bare-metal stent only” and the
last row should have been labeled “1 Drug-eluting stent.” This article was cor-
rected online.
1. Berwanger O, Santucci EV, de Barros E Silva PGM, et al; SECURE-PCI
Investigators. Effect of loading dose of atorvastatin prior to planned
percutaneous coronary intervention on major adverse cardiovascular events in
acute coronary syndrome: the SECURE-PCI randomized clinical trial. JAMA.
2018;319(13):1331-1340. doi:10.1001/jama.2018.2444
Guidelines for Letters
Letters discussing a recent JAMA article should be submitted within 4
weeks of the article's publication in print. Letters received after 4 weeks
will rarely be considered. Letters should not exceed 400 words of text
and 5 references and may have no more than 3 authors. Letters report-
ing original research should not exceed 600 words of text and 6 refer-
ences and may have no more than 7 authors. They may include up to 2
tables or figures but online supplementary material is not allowed. All
letters should include a word count. Letters must not duplicate other ma-
terial published or submitted for publication. Letters not meeting these
specifications are generally not considered. Letters being considered for
publication ordinarily will be sent to the authors of the JAMA article, who
will be given the opportunity to reply. Letters will be published at the
discretion of the editors and are subject to abridgement and editing. Fur-
ther instructions can be found at http://jamanetwork.com/journals/jama
/pages/instructions-for-authors. A signed statement for authorship cri-
teria and responsibility, financial disclosure, copyright transfer, and
acknowledgment and the ICMJE Form for Disclosure of Potential Con-
flicts of Interest are required before publication. Letters should be sub-
mitted via the JAMA online submission and review system at https:
//manuscripts.jama.com. For technical assistance, please contact
jama-letters@jamanetwork.org.
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